AtriCure Stock Forecast, Price & News

+0.11 (+0.16 %)
(As of 04/22/2021 12:00 AM ET)
Today's Range
Now: $70.02
50-Day Range
MA: $64.88
52-Week Range
Now: $70.02
Volume377,586 shs
Average Volume377,209 shs
Market Capitalization$3.19 billion
P/E RatioN/A
Dividend YieldN/A
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States, Europe, Asia, and internationally. It offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. The company also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used to treat symptomatic persistent and long-standing persistent atrial fibrillation patients; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, it sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; COBRA Fusion Surgical Ablation System; Fusion Magnetic Retriever System; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. The company markets and sells its products through independent distributors and direct sales personnel. AtriCure, Inc. was incorporated in 2000 and is headquartered in Mason, Ohio.
AtriCure logo

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
Current SymbolNASDAQ:ATRC
Year FoundedN/A



Sales & Book Value

Annual Sales$230.81 million
Book Value$6.25 per share


Net Income$-35,190,000.00


Market Cap$3.19 billion
Next Earnings Date4/27/2021 (Confirmed)


AtriCure (NASDAQ:ATRC) Sets New 52-Week High at $71.16
April 22, 2021 |
AtriCure (NASDAQ:ATRC) Hits New 1-Year High at $68.22
April 17, 2021 |
AtriCure (NASDAQ:ATRC) PT Raised to $77.00
April 12, 2021 |
AtriCure Names B. Kristine Johnson Board Chair
April 8, 2021 |
See More Headlines


Overall MarketRank

1.34 out of 5 stars

Medical Sector

751st out of 2,024 stocks

Surgical & Medical Instruments Industry

79th out of 169 stocks

Analyst Opinion: 1.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
+0.11 (+0.16 %)
(As of 04/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ATRC News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

AtriCure (NASDAQ:ATRC) Frequently Asked Questions

Is AtriCure a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AtriCure stock.
View analyst ratings for AtriCure
or view top-rated stocks.

What stocks does MarketBeat like better than AtriCure?

Wall Street analysts have given AtriCure a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but AtriCure wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting AtriCure?

AtriCure saw a decrease in short interest during the month of March. As of March 15th, there was short interest totaling 1,970,000 shares, a decrease of 23.9% from the February 28th total of 2,590,000 shares. Based on an average daily trading volume, of 402,400 shares, the days-to-cover ratio is currently 4.9 days.
View AtriCure's Short Interest

When is AtriCure's next earnings date?

AtriCure is scheduled to release its next quarterly earnings announcement on Tuesday, April 27th 2021.
View our earnings forecast for AtriCure

How can I listen to AtriCure's earnings call?

AtriCure will be holding an earnings conference call on Tuesday, April 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were AtriCure's earnings last quarter?

AtriCure, Inc. (NASDAQ:ATRC) announced its quarterly earnings results on Monday, February, 22nd. The medical device company reported ($0.28) EPS for the quarter, hitting the Zacks' consensus estimate of ($0.28). The medical device company earned $57.70 million during the quarter, compared to analyst estimates of $57.96 million. AtriCure had a negative net margin of 21.74% and a negative trailing twelve-month return on equity of 14.83%. The firm's quarterly revenue was down 5.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.37) earnings per share.
View AtriCure's earnings history

How has AtriCure's stock price been impacted by COVID-19 (Coronavirus)?

AtriCure's stock was trading at $35.28 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ATRC stock has increased by 98.5% and is now trading at $70.02.
View which stocks have been most impacted by COVID-19

What guidance has AtriCure issued on next quarter's earnings?

AtriCure updated its FY21 earnings guidance on Tuesday, February, 23rd. The company provided earnings per share guidance of ~($1.15) for the period, compared to the Thomson Reuters consensus estimate of ($0.80). The company issued revenue guidance of ~$250 million, compared to the consensus revenue estimate of $257.16 million.

What price target have analysts set for ATRC?

7 analysts have issued twelve-month target prices for AtriCure's stock. Their forecasts range from $52.00 to $78.00. On average, they expect AtriCure's stock price to reach $67.14 in the next twelve months. This suggests that the stock has a possible downside of 4.1%.
View analysts' price targets for AtriCure
or view top-rated stocks among Wall Street analysts.

Who are AtriCure's key executives?

AtriCure's management team includes the following people:
  • Mr. Michael H. Carrel, CEO, Pres & Director (Age 50, Pay $1.83M)
  • Mr. Douglas J. Seith, Chief Operating Officer (Age 55, Pay $967.43k)
  • Mr. Salvatore Privitera J.D., Chief Technical Officer (Age 54, Pay $639.99k)
  • Mr. Justin J. Noznesky, Chief Marketing & Strategy Officer (Age 43, Pay $632.13k)
  • Ms. Angela L. Wirick, Chief Financial Officer
  • Dr. Vinayak Doraiswamy, Chief Scientific Officer
  • Mr. Karl Dahlquist, Chief Legal Officer
  • Ms. Tonya Austin, Chief HR Officer
  • Valerie Storch-Willhaus, Sr. Director of Corp. Marketing & Communications
  • Mr. Theodore L. Polin, Corp. Sec.

What is Michael Carrel's approval rating as AtriCure's CEO?

25 employees have rated AtriCure CEO Michael Carrel on Michael Carrel has an approval rating of 100% among AtriCure's employees. This puts Michael Carrel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of AtriCure's key competitors?

What other stocks do shareholders of AtriCure own?

What is AtriCure's stock symbol?

AtriCure trades on the NASDAQ under the ticker symbol "ATRC."

Who are AtriCure's major shareholders?

AtriCure's stock is owned by a variety of institutional and retail investors. Top institutional investors include Clarus Group Inc. (0.22%), First Bank & Trust (0.01%) and Harbor Investment Advisory LLC (0.00%). Company insiders that own AtriCure stock include Douglas J Seith, Justin J Noznesky, M Andrew Wade, Mark A Collar, Michael H Carrel, Regina E Groves, Salvatore Privitera and Scott William Drake.
View institutional ownership trends for AtriCure

Which major investors are buying AtriCure stock?

ATRC stock was acquired by a variety of institutional investors in the last quarter, including Clarus Group Inc., First Bank & Trust, and Harbor Investment Advisory LLC. Company insiders that have bought AtriCure stock in the last two years include Regina E Groves, and Scott William Drake.
View insider buying and selling activity for AtriCure
or or view top insider-buying stocks.

How do I buy shares of AtriCure?

Shares of ATRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AtriCure's stock price today?

One share of ATRC stock can currently be purchased for approximately $70.02.

How much money does AtriCure make?

AtriCure has a market capitalization of $3.19 billion and generates $230.81 million in revenue each year. The medical device company earns $-35,190,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis.

How many employees does AtriCure have?

AtriCure employs 750 workers across the globe.

What is AtriCure's official website?

The official website for AtriCure is

Where are AtriCure's headquarters?

AtriCure is headquartered at 7555 INNOVATION WAY, MASON OH, 45040.

How can I contact AtriCure?

AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The medical device company can be reached via phone at 513-755-4100.

This page was last updated on 4/22/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.